Overview

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

Status:
NOT_YET_RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of CM9241GRU versus placebo in the treatment of perennial allergic rhinitis.
Phase:
PHASE3
Details
Lead Sponsor:
Ache Laboratorios Farmaceuticos S.A.